Published in PLoS One on February 14, 2014
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science (2016) 1.52
Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer (2014) 1.22
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res (2015) 1.18
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer (2015) 1.03
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res (2015) 1.01
Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal (2015) 0.99
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget (2015) 0.98
Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. J Biol Chem (2014) 0.97
PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology (2015) 0.93
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One (2015) 0.90
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer (2016) 0.88
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget (2016) 0.86
PD-L1 Expression in Lung Cancer. J Thorac Oncol (2016) 0.85
Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist (2016) 0.84
Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. Oncoimmunology (2015) 0.83
CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers. Cancer Immunol Res (2015) 0.81
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res (2016) 0.81
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. Oncologist (2016) 0.80
The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget (2016) 0.79
X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis (2016) 0.78
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. Diagn Pathol (2016) 0.78
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus (2016) 0.78
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Int J Mol Sci (2017) 0.78
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med (2017) 0.75
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. J Breast Cancer (2016) 0.75
Mechanism of immune evasion in breast cancer. Onco Targets Ther (2017) 0.75
Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press) (2016) 0.75
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) (2015) 0.75
New Immunotherapy Strategies in Breast Cancer. Int J Environ Res Public Health (2017) 0.75
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. Oncotarget (2017) 0.75
Theranostic Gold Nanoantennas for Simultaneous Multiplexed Raman Imaging of Immunomarkers and Photothermal Therapy. ACS Omega (2017) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer (2007) 3.71
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (2013) 2.75
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori (2012) 2.55
Interaction of human PD-L1 and B7-1. Mol Immunol (2008) 2.48
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett (2006) 2.24
Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol (2008) 1.79
Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res (2010) 1.74
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63
Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat (2004) 1.41
The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat (2011) 1.15
Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets (2011) 1.12
Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatology (Oxford) (2008) 0.99
Interferon regulatory factor 2 binding protein 2 is a new NFAT1 partner and represses its transcriptional activity. Mol Cell Biol (2011) 0.95
Identification of a phosphorylation-dependent nuclear localization motif in interferon regulatory factor 2 binding protein 2. PLoS One (2011) 0.91
[Expression of paxillin in breast cancer cell with high and low metastatic potentiality]. Sichuan Da Xue Xue Bao Yi Xue Ban (2010) 0.81